Am­gen, As­traZeneca speed to­ward fil­ing next-gen an­ti­body for asth­ma af­ter un­cork­ing full late-stage da­ta

5 years ago
R&D

Mark Mal­lon charts post-Iron­wood course by tak­ing CEO job at NeoGe­nomics; Glax­o­SmithK­line vet Feng Ren joins In­sil­i­co ...

5 years ago
Peer Review

Covid-19 roundup: US se­cures 100,000 dos­es of Eli Lil­ly's an­ti­body cock­tail; Mer­ck­'s $356M sup­ply deal on hold as FDA ...

5 years ago
Coronavirus

NK cell ther­a­py play­er Arti­va makes some more noise, pulling in $120M Se­ries B less than a month af­ter Mer­ck deal

5 years ago
Financing
Cell/Gene Tx

The path to NASH: un­der­stand­ing the role of se­vere obe­si­ty in a com­plex, mul­ti-sys­tem dis­ease

5 years ago
Biotech Voices

Roivant par­lays a $450M chunk of eq­ui­ty in biotech buy­out, grab­bing a com­pu­ta­tion­al group to dri­ve dis­cov­ery work

5 years ago
Deals

With dust set­tled on ac­tivist at­tack, Lau­rence Coop­er leaves Zio­pharm to a new board

5 years ago
People

Why not? Sarep­ta’s third Duchenne MD drug sails to ac­cel­er­at­ed ap­proval

5 years ago
Pharma
FDA+

Avid Bioser­vices, with re­cent IPO and Covid-19 part­ner­ship in hand, launch­es 2nd phase of fa­cil­i­ty ex­pan­sion

5 years ago
Outsourcing
Manufacturing

Biden wants a re­view of the API sup­ply chain. Will that par­lay in­to an ef­fort to 'on­shore' drug man­u­fac­tur­ing?

5 years ago
Outsourcing
Manufacturing

In search of 'house­hold health­care brands of the fu­ture,' Fore­site Cap­i­tal rais­es $969M to sa­ti­ate a tech-heavy ...

5 years ago
Financing

Xen­cor, UCLA to part­ner for new ther­a­peu­tic an­ti­bod­ies; Schrödinger ex­pands part­ner­ship with Google Cloud

5 years ago
News Briefing

Re­gen­eron halts place­bo en­roll­ment in Covid-19 cock­tail tri­al af­ter IDMC finds 'clear' ef­fi­ca­cy — but there are no ...

5 years ago
Coronavirus

S&P ex­pects steady ero­sion in Big Phar­ma's cred­it pro­file in 2021 as new M&A deals roll in — but don't ...

5 years ago
Pharma

CMO Tal Zaks bids Mod­er­na a sur­prise adieu as biotech projects $18.4B in rev­enue, plots post-Covid ex­pan­sion

5 years ago
People
Manufacturing

Dutch biotech In­travacc seeks to bol­ster Nether­lands vac­cine man­u­fac­tur­ing abil­i­ties with new plants

5 years ago
Manufacturing

Fol­low biotechs go­ing pub­lic with the End­points News IPO Track­er

5 years ago
Editor's note

Mer­ck takes a swing at the IL-2 puz­zle­box with a $1.85B play for buzzy Pan­dion and its au­toim­mune hope­fuls

5 years ago
Deals
Pharma

Sean Nolan gath­ers AveX­is alum­ni to launch an­oth­er biotech. Is it an­oth­er race-to-IPO?

5 years ago
Startups
R&D

Covid-19 roundup: Pfiz­er/BioN­Tech shot just as ef­fec­tive in re­al world, study says, as pair preps vari­ant boost­er ...

5 years ago
Coronavirus

Biden is look­ing be­yond Wood­cock or Sharf­stein for FDA com­mis­sion­er — re­port

5 years ago
People
FDA+

Glax­o­SmithK­line re­thinks strat­e­gy for Covid-19 an­ti­body — not the Vir ones — af­ter tri­al flop. Is there hope in ...

5 years ago
R&D
Coronavirus

Flag­ship up­start Cel­lar­i­ty gath­ers $123M to fi­nance its ex­plo­ration of cell be­hav­ior, blaz­ing a new path to build­ing ...

5 years ago
Financing
Startups

Mod­er­na's Stéphane Ban­cel plans to dou­ble down on vac­cine pro­duc­tion, new vari­ants as mR­NA rules in pan­dem­ic fight

5 years ago
R&D
First page Previous page 729730731732733734735 Next page Last page
A service from the Financial Times